Health Care • Biotechnology: Pharmaceutical Preparations
$85.95 ▼ -0.33
(-0.38%)
MKT CAP: $9.29B • VOL: 1.19M
52W L $29 52W H $126
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$72
MEDIAN
$96
MEAN
$98
HIGH
$117
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CORT TAPE
CORT // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $104.00 | $98.84 | 2025-02-14 | $78.21 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $108.30 | $101.42 | 2025-02-06 | $80.79 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $97.98 | $94.55 | 2025-01-29 | $82.51 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $87.67 | — | 2025-01-17 | $84.23 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $75.64 | $81.65 | 2025-01-09 | $76.50 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $102.28 | $89.39 | 2024-12-18 | $74.78 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $83.37 | $86.81 | 2024-12-04 | $79.93 | -4.3% | 48% | C |